Stock Monitor: Milestone Scientific Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 17, 2018 / Active-Investors.com has just released a free research report on Nxstage Medical, Inc. (NASDAQ: NXTM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NXTM as the Company's latest news hit the wire. On April 13, 2018, the Company announced that the Company's Medisystems products division has released MasterGuard® Plus, its latest innovation in AVF needle safety. Medisystems will showcase MasterGuard® Plus during the American Nephrology Nurses Association Conference from April 15-17, 2018, in Las Vegas. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Milestone Scientific Inc. (NYSE American: MLSS), which also belongs to the Healthcare sector as the Company Nxstage Medical. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=MLSS
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Nxstage Medical most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=NXTM
MasterGuard® Plus Leverages Proven Safety Features of Medisystems' MasterGuard® Needle Guard
MasterGuard® Plus leverages the proven safety features of Medisystems' MasterGuard® needle guard and offers new features designed to enhance dialysis staff safety by helping to prevent needlestick injuries. More specifically, MasterGuard® Plus offers new intuitive ergonomic and patented safety features including a redesigned needle lock designed to increase security after retraction.
Early Customer Feedback of MasterGuard® Plus has been Very Positive
Joseph E. Turk, President of NxStage, mentioned that early customer feedback has been very positive, validating many of the benefits the Company expected.
Joseph added that NxStage is very excited to bring these enhanced features to dialysis staff and patients while maintaining the ease of use that they have come to expect from Medisystems products.
NxStage to Merge with Fresenius Medical Care
In October 217, NxStage's stockholders voted to adopt the previously announced Agreement and Plan of Merger, dated August 07, 2017, with Fresenius Medical Care Holdings, Inc., whereby Fresenius will acquire NxStage through a wholly-owned subsidiary of Fresenius. The approval of the Merger Agreement fulfilled an important condition for the full acquisition of NxStage. Upon completion of the merger, NxStage's stockholders would be entitled to receive $30 in cash, without interest, for each share of NxStage's common stock that such stockholder owns. The merger, expected to be completed in 2018, remains subject to additional customary closing conditions, including regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act in the US.
About MasterGuard® Plus
MasterGuard® Plus needles have ultra-thin walls, precisely ground bevels, and siliconized needle for smooth cannulation. The needles have flexible wings with interlocking grips for precise control of the needle, and rotatable hub with bevel indicator dots (some codes) to reduce the risk of tissue damage associated with rotation of fixed-wing needles. MasterGuard® Plus needles are designed with FingerShield® anchor to protect the fingers most at risk of needlesticks, and FingerShield to provide a barrier between the pressure-holding fingers and the sharp tip of the needle
About Medisystems
Medisystems offers products that are designed to provide clinical, safety, and economic advantages. Medisystems is committed to understanding Nxstage customers' needs so the products can be efficiently implemented across care settings. The Company's bloodlines, needles, and accessories are helping to move the industry forward through safe, convenient, and cost-effective uses across hemodialysis, apheresis, and plasma collection centers.
About Nxstage Medical, Inc.
Founded in 1998 and headquartered in Lawrence, Massachusetts, NxStage Medical is a leading medical technology company that develops, manufactures, and markets innovative products for the treatment of end-stage renal disease (ERSD) and acute kidney failure. The Company also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD.
Stock Performance Snapshot
April 16, 2018 - At Monday's closing bell, Nxstage Medical's stock slightly rose 0.12%, ending the trading session at $25.80.
Volume traded for the day: 143.64 thousand shares.
Stock performance in the last month – up 6.74%; previous three-month period – up 4.16%; and year-to-date - up 6.48%
After yesterday's close, Nxstage Medical's market cap was at $1.73 billion.
Price to Earnings (P/E) ratio was at 44.41.
The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry. This sector was up 0.5% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
